Inhibitors of monocyte chemoattractant protein-1/CC ligand 2 and its receptor CCR2

O. M Z Howard, Teizo Yoshimura

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Chemoattractant cytokines (chemokines) have been shown to be pro-inflammatory and are thus likely targets for therapeutic intervention. An agent that interferes with directed migration of leukocytes to an inflammatory site is potentially a candidate anti-inflammatory drug. A specific chemokine, monocyte chemoattractant protein (MCP)-1 or CC ligand 2 (CCL2), and its receptor, CC-chemokine receptor 2 (CCR2), have been implicated in both acute and chronic inflammatory and autoimmune diseases associated with infiltration of monocytes, macrophages, dendritic cells, NK cells, basophils and memory T-cells. Genetic modification of CCL2 and CCR2 in murine models has demonstrated the potential for antagonists to prevent atherogenic vascular disease and autoimmune inflammatory diseases. Modified CCL2 peptides, which still bind but no longer activate CCR2, demonstrated the therapeutic potential of CCL2 inhibitors in animal models of arthritis. Several classes of small molecular weight CCL2 inhibitors have also been shown to inhibit chemotaxis in response to CCL2 in vitro and in animal models. However, more work is needed to establish the clinical efficacy of these CCL2 inhibitors.

Original languageEnglish
Pages (from-to)1147-1151
Number of pages5
JournalExpert Opinion on Therapeutic Patents
Volume11
Issue number7
DOIs
Publication statusPublished - 2001
Externally publishedYes

Fingerprint

CCR2 Receptors
Chemokine CCL2
Ligands
Disease
animal
subversion
Chemotactic Factors
Autoimmune Diseases
candidacy
migration
drug
Animal Models
Formyl Peptide Receptor
Cytokines
Cytokine Receptors
Basophils
Chemotaxis
Vascular Diseases
Natural Killer Cells
Dendritic Cells

Keywords

  • Atherogenic disease
  • CCL2
  • CCR2
  • Inflammation
  • Monocyte chemoattractant proteins
  • Tumour

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Pharmacology
  • Law

Cite this

Inhibitors of monocyte chemoattractant protein-1/CC ligand 2 and its receptor CCR2. / Howard, O. M Z; Yoshimura, Teizo.

In: Expert Opinion on Therapeutic Patents, Vol. 11, No. 7, 2001, p. 1147-1151.

Research output: Contribution to journalReview article

@article{c20c02180aef428d8e45db23a50ce764,
title = "Inhibitors of monocyte chemoattractant protein-1/CC ligand 2 and its receptor CCR2",
abstract = "Chemoattractant cytokines (chemokines) have been shown to be pro-inflammatory and are thus likely targets for therapeutic intervention. An agent that interferes with directed migration of leukocytes to an inflammatory site is potentially a candidate anti-inflammatory drug. A specific chemokine, monocyte chemoattractant protein (MCP)-1 or CC ligand 2 (CCL2), and its receptor, CC-chemokine receptor 2 (CCR2), have been implicated in both acute and chronic inflammatory and autoimmune diseases associated with infiltration of monocytes, macrophages, dendritic cells, NK cells, basophils and memory T-cells. Genetic modification of CCL2 and CCR2 in murine models has demonstrated the potential for antagonists to prevent atherogenic vascular disease and autoimmune inflammatory diseases. Modified CCL2 peptides, which still bind but no longer activate CCR2, demonstrated the therapeutic potential of CCL2 inhibitors in animal models of arthritis. Several classes of small molecular weight CCL2 inhibitors have also been shown to inhibit chemotaxis in response to CCL2 in vitro and in animal models. However, more work is needed to establish the clinical efficacy of these CCL2 inhibitors.",
keywords = "Atherogenic disease, CCL2, CCR2, Inflammation, Monocyte chemoattractant proteins, Tumour",
author = "Howard, {O. M Z} and Teizo Yoshimura",
year = "2001",
doi = "10.1517/13543776.11.7.1147",
language = "English",
volume = "11",
pages = "1147--1151",
journal = "Expert Opinion on Therapeutic Patents",
issn = "1354-3776",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - Inhibitors of monocyte chemoattractant protein-1/CC ligand 2 and its receptor CCR2

AU - Howard, O. M Z

AU - Yoshimura, Teizo

PY - 2001

Y1 - 2001

N2 - Chemoattractant cytokines (chemokines) have been shown to be pro-inflammatory and are thus likely targets for therapeutic intervention. An agent that interferes with directed migration of leukocytes to an inflammatory site is potentially a candidate anti-inflammatory drug. A specific chemokine, monocyte chemoattractant protein (MCP)-1 or CC ligand 2 (CCL2), and its receptor, CC-chemokine receptor 2 (CCR2), have been implicated in both acute and chronic inflammatory and autoimmune diseases associated with infiltration of monocytes, macrophages, dendritic cells, NK cells, basophils and memory T-cells. Genetic modification of CCL2 and CCR2 in murine models has demonstrated the potential for antagonists to prevent atherogenic vascular disease and autoimmune inflammatory diseases. Modified CCL2 peptides, which still bind but no longer activate CCR2, demonstrated the therapeutic potential of CCL2 inhibitors in animal models of arthritis. Several classes of small molecular weight CCL2 inhibitors have also been shown to inhibit chemotaxis in response to CCL2 in vitro and in animal models. However, more work is needed to establish the clinical efficacy of these CCL2 inhibitors.

AB - Chemoattractant cytokines (chemokines) have been shown to be pro-inflammatory and are thus likely targets for therapeutic intervention. An agent that interferes with directed migration of leukocytes to an inflammatory site is potentially a candidate anti-inflammatory drug. A specific chemokine, monocyte chemoattractant protein (MCP)-1 or CC ligand 2 (CCL2), and its receptor, CC-chemokine receptor 2 (CCR2), have been implicated in both acute and chronic inflammatory and autoimmune diseases associated with infiltration of monocytes, macrophages, dendritic cells, NK cells, basophils and memory T-cells. Genetic modification of CCL2 and CCR2 in murine models has demonstrated the potential for antagonists to prevent atherogenic vascular disease and autoimmune inflammatory diseases. Modified CCL2 peptides, which still bind but no longer activate CCR2, demonstrated the therapeutic potential of CCL2 inhibitors in animal models of arthritis. Several classes of small molecular weight CCL2 inhibitors have also been shown to inhibit chemotaxis in response to CCL2 in vitro and in animal models. However, more work is needed to establish the clinical efficacy of these CCL2 inhibitors.

KW - Atherogenic disease

KW - CCL2

KW - CCR2

KW - Inflammation

KW - Monocyte chemoattractant proteins

KW - Tumour

UR - http://www.scopus.com/inward/record.url?scp=0034944414&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034944414&partnerID=8YFLogxK

U2 - 10.1517/13543776.11.7.1147

DO - 10.1517/13543776.11.7.1147

M3 - Review article

AN - SCOPUS:0034944414

VL - 11

SP - 1147

EP - 1151

JO - Expert Opinion on Therapeutic Patents

JF - Expert Opinion on Therapeutic Patents

SN - 1354-3776

IS - 7

ER -